Europe: EMA assessing reports of Guillain-Barre syndrome with AstraZeneca’s coronavirus vaccine VaxZevria

“As part of the review of the regular pandemic summary safety reports for Vaxzevria, AstraZeneca’s Covid-19 vaccine, the PRAC is analysing data provided by the marketing authorisation holder on cases of Guillain-Barre syndrome (GBS) [1] reported following vaccination.  More...